## DEPARTMENT OF HEALTH AND HUMAN SERVICES

# Administration for Children and Families

Deviation From Competition for Change in Scope and a Supplement to ARC of the United States "Medicaid Reference Desk"

**AGENCY:** Administration on Developmental Disabilities, ACF, FDHHS.

**ACTION:** Notice.

**SUMMARY:** The original and proposed objectives were designed to address the needs of people to have a timely access to information regarding the structure and functioning of State Medicaid programs and Federal level changes that have an impact on State systems of support and also provide a Web site that includes developing highly accessible alternative formats for delivering information to individuals with various disabilities through technology.

The ARC of the United States, the Administration on Developmental Disabilities and the Centers for Medicare and Medicaid Services (CMS) will partner to implement the "Guide to Choosing a Medicare Approved Drug Discount Card" to include a web-based product with audio and video clips for individuals with intellectual disabilities and limited literacy skills. This will be accomplished by the Centers for Medicare and Medicaid Services providing funding to supplement this grant in the amount of \$12,000. This grant can be accomplished within the period of 30 days to coincide with the ongoing project period which will end September 30, 2004.

This supplement will allow the ARC of the United States to translate an online resource for States and organizations a plain language version of the "Guide to Choosing a Medicare Approved Drug Discount Card." The translation will include brief audio and video clips explaining each important detail specified in the Guide. This will increase peoples understanding especially those with language and literacy needs. Making this resource available directly to States and to the wide network of advocacy organizations will prevent a great deal of confusion and even more, it will save ADD and CMS personnel countless hours in telephone and on-site personal assistance.

#### FOR FURTHER INFORMATION CONTACT:

Administration for Children and Families (ACF), Debbie Powell, Director, Office of Operations and Discretionary Grants, 370 L'Enfant Promenade, SW., MS 405D, Washington, DC 20447, Telephone: (202) 690–6590.

Dated: August 13, 2004.

#### Patricia A. Morrissey,

Commissioner, Administration on Developmental Disabilities.

[FR Doc. 04–19173 Filed 8–19–04; 8:45 am]

BILLING CODE 4184-01-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### **National Institutes of Health**

# National Cancer Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)6), title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Cancer Institute Special Emphasis Panel, Development and Application of High-Throughput Proteomics Technologies.

Date: September 14, 2004. Time: 1 p.m. to 4 p.m.

Agenda: To review and evaluate contract proposals.

Place: National Institutes of Health, 6130 Executive Blvd., Rockville, MD 20852. (Telephone Conference Call).

Contact Person: Lalita D. Palekar, PhD. Scientific Review Administrator, Special Review and Resources Branch, Division of Extramural Activities, National Cancer Institute, National Institutes of Health, 6116 Executive Boulevard, Room 8105, Bethesda, MD 20892–7405. (301) 496–7575.

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number, and when applicable, the business or professional affiliation of the interested person.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS) Dated: August 13, 2004.

### LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 04–19083 Filed 8–19–04; 8:45 am]

BILLING CODE 4140-01-M

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### **National Institutes of Health**

# National Cancer Institute; Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the meeting of the President's Cancer Panel.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meeting will be closed to the public in accordance with the provisions set forth in section 552b(c)(9)(B), Title 5 U.S.C., as amended because the premature disclosure of information and the discussions would be likely to significantly frustrate implementation of recommendations.

Name of Committee: President's Cancer Panel.

Date: August 30-31, 2004.

Open: August 30, 2004, 8 a.m. to 4 p.m. Agenda: Translating Research into Clinical Practice.

Place: Grand Hyatt San Francisco, 345 Stockton Street, San Francisco, CA 94108. Closed: August 31, 2004, 9 a.m. to 12 p.m. Agenda: To review and evaluate prepublication manuscripts on Translating Research into Clinical Practices.

Place: Grand Hyatt San Francisco, 345 Stockton Street, San Francisco, CA 94108. Contact Person: Maureen O. Wilson, PhD, Executive Secretary, National Cancer Institute, National Institutes of Health, 31 Center Drive, Building 31, Room 3A18, Bethesda, MD 20892, (301) 496–1148.

This notice is being published less than 15 days prior to the meeting due to scheduling conflicts.

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and, when applicable, the business or professional affiliation of the interested person.

Information is also available on the Institute's/Center's home page: deainfo.nci.nih.gov/advisory/pcp/pcp.htm, where an agenda and any additional information for the meeting will be posted when available.